PIPE-791, a potent brain-penetrant selective LPA1 antagonist, reduces neuroinflammation in vivo 

/in , /by

Geraldine C Edu, Michael M Poon, Ariana O Lorenzana, Alexander Broadhead, Chris Baccei, Jeff Roppe, Thomas Schrader, Lino Valdez, Yifeng Xiong, Austin Chen, and Daniel S Lorrain

Presented at Neuroscience 2022

Discovery of remyelination therapeutics that overcome the effects of inflammatory macrophages on oligodendrocyte formation

/in , /by

Kym I Lorrain, Michael M Poon, Alexander Broadhead, Geraldine Edu, Jonah R Chan, Austin Chen, Daniel S Lorrain

Presented at Neuroscience 2022

LPA1 Expression in CNS Fibroblasts During Multiple Sclerosis

/in , /by

Michael M. Poon, Didier Bagnol, Austin C. Chen, Daniel S. Lorrain

Presented at ACTRIMS Forum 2026

Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders

/in , /by

Austin Chen, Christopher Baccei, Jill Baccei, Alexander Broadhead, Kym I. Lorrain, Michael M. Poon, Jeffrey Roppe, Thomas O. Schrader, Karin J. Stebbins, Lino Valdez, Yifeng Xiong, and Daniel S. Lorrain

©2026 Contineum Therapeutics Terms of Use Privacy Policy Linkedin Linkedin